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This work provides evidence that the robust myoblast diﬀerentiation observed in L6E9 cells is causally linked to deﬁciency
of myostatin, which, conversely, has been found to be expressed in C2C12 cells. However, despite the absence of endogenous
myostatin, L6E9 myoblasts expressed functional Activin receptors type II (ActRIIs) and follistatin as well as the highly related
TGF-β members Activins and GDF11, suggesting that in this cell line the regulation of ﬁber size might be under the control of
multiple regulators regardless of myostatin. In line with this hypothesis, delivery of a dominant-negative ActRIIb form or the
increase of follistatin, as obtained via Trichostatin treatment or stable transfection of a short human follistatin form, enhanced
the L6E9 cell diﬀerentiation and further increased the size of myotubes, suggesting that L6E9 myoblasts provide a spontaneous
myostatin knock-out in vitro model to study TGF-β ligands involved in developmental regulation of ﬁber size.
1.Introduction
Over the last years, the TGF-β member myostatin has
gained particular relevance because of its ability to exert a
profound eﬀect on muscle metabolism, by regulating the
myoﬁber size in response to physiological or pathological
conditions [1–5]. Of note, myostatin loss-of-function due
to naturally occurring mutations into its gene triggers
muscle mass increase in cattle [6], dogs [7], and humans
as well [8], whereas targeted disruption of myostatin gene
produces a huge muscle mass in mice [1]. On the con-
trary, systematic administration of myostatin induces muscle
cachexia [9], and several conditions which cause muscle
atrophy enable increase of myostatin expression [10–12].
Therefore, reduced or excessive myostatin signaling aﬀects
the muscle metabolism by inducing muscle hypertrophy
and atrophy, respectively. Normally, myostatin signals in
myoblaststhroughacanonicalTGF-βsignalingpathway,that
occurs after binding with Activin receptors (ActRIIs) [3]
and the subsequent activation of a Smad ternary complex
[13, 14], which in turn drives to a transcriptional program
potentially involved in muscle remodeling. In line with
this evidence, the block of myostatin pathway in mice by
delivering a dominant-negative ActRIIb form triggers an
increase of muscle mass [15]. On the other side, follistatin
has been described as a powerful inducer of muscle mass,
due to its ability to bind and neutralize the myostatin
activity [15–18]. However, follistatin transgenic mice display
bigger muscles than myostatin null mice [15], and breeding
transgenic follistatin mice with myostatin null mice triggers
quadrupling of muscle mass [19], suggesting that follistatin
can promote muscle growth also independently of its action2 Journal of Biomedicine and Biotechnology
on myostatin. To date, most of the in vitro myoblast
studies relied on the use of mouse C2C12 and rat L6E9
cells, two immortalized lines whose myogenesis process
recapitulates the phases of embryonic muscle diﬀerentiation,
when myoblasts undergo alignment, fusion, and growth in
the attempt to form a contractile myoﬁber. In this work,
by comparing the diﬀerentiation between C2C12 and L6E9
myoblasts, we hypothesize that the more robust formation
of myotubes in L6E9 is causally linked to deﬁciency of myo-
statin, which is expressed in C2C12 myoblasts. Additionally,
since we recognized that ActRIIs and follistatin are expressed
inL6E9cells,weveriﬁedwhetherthedeliveryofadominant-
negative ActRIIb form or the overexpression of follistatin
might inﬂuence the diﬀerentiation and the development of
L6E9 myotubes irrespective of myostatin. Finally, RT-PCR
analysis was carried out to detect whether L6E9 cells express
Activins [20, 21] and GDF11 [20, 22], which are TGF-β
members supposed to play redundant roles with myostatin
to regulate the muscle mass.
2.MaterialsandMethods
2.1. Materials. A l lr e a g e n t sw e r ef r o mS i g m a - A l d r i c h ,i fn o t
otherwise indicated.
2.2. Cell Cultures, Cell Staining, and Myotube Quantiﬁcation.
C2C12 and L6E9 myoblasts were maintained in humidiﬁed
incubator at 37◦C and 5% CO2 in DMEM high glucose
supplemented with 10% or 20% FBS, respectively, and
100μg/mL penicillin-streptomycin. To induce diﬀerentia-
tion, preconﬂuent C2C12 and L6E9 myoblasts were cultured
in a medium consisting of DMEM supplemented with
2% HS or 1% FBS, respectively. To visualize myotubular
structures, cells were ﬁxed in methanol and stained with
Giemsa reactive. To quantify the myotube size, an Image
ProPlus software (version 6.2) was used; the average size of
myotubes was the mean of 100 measurements, as obtained
after measuring 10 myotubes in 10 diﬀerent ﬁelds.
2.3. Drug Treatments. Diﬀerentiated L6E9 myotubes were
treated with 100–500ng/mL human-puriﬁed recombinant
myostatin (BioVision). Trichostatin A (50nM) was adminis-
tered to preconﬂuent cells up to 16–18 hours before addition
of the diﬀerentiation medium.
2.4. Animals. Experiments were performed according to
the European Community Council Directive, November
1986 (86/609/EEC). Wistar rats and C57BL/6 mice were
anesthetized with chloral hydrate (400mg/kg) and then
sacriﬁced. Gastrocnemius muscles were collected and imme-
diatelyfrozenbyliquidnitrogenbeforeproceedingwithRNA
isolation.
2.5. RNA Isolation and Semiquantitative RT-PCR Analysis.
Total RNA was isolated by Trireagent method, digested with
DNase (DNA-free, Ambion), and reverse transcribed (2μg)
in the presence of 400 units of MMLV-RT (Promega). The
following primers (forward and reverse, 250nM each) were
designed to amplify both the mouse and rat transcripts.
(i) Activin A (accession number NM 008380), 5 -TTC-
TGTTGGCAAGTTGCTGGATTA-3  and 5 -AAA-
GGTGATGATCTCCGAGGTCTG-3 ,
(ii) Activin B (accession number NM 008381), 5 -TCT-
TCGTCTCTAACGAAGGCAACC-3  and 5 -ATG-
AGCCGAAAGTCGATGAAGAAC-3 ,
(iii) Activin receptor type IIa (accession number NM
007396), 5 -GCCCACTTCAAATCCTGTTACACC-
3  and 5 -ATCCACACTGGTGCCTCTTTTCTC-3 ,
(iv) Activin receptor type IIb (accession number NM
007397), 5 -CTCGGGAGTGCATCTACTACAACG-
3  and 5 -TTCCGATGACGATACATCCAGAAG-3 ,
(v) Follistatin (accession number NM 008046), 5 -CTC-
TTCAAGTGGATGATTTTC-3  and 5 -ACAGTA-
GGCATTATTGGTCTG-3 ,
(vi) Glyceraldehyde-3-phosphate dehydrogenase (gapdh,
accession number NM 008084), 5 -GGTGCTGAG-
TATGTCGTGGAGTC-3  and 5 -GGACTGTGG-
TCATGAGCCCTTCC-3 ,
(vii) Growth diﬀerentiation factor 11 (GDF11, accession
number NM 010272), 5 -AGAGGACGAGTACCA-
CGCTACCAC-3  and 5 -CACTTGCTTGAAGTC-
GATGCTCTG-3 ,
(viii) Myostatin (accession number NM 010834), 5 -AAC-
CCATGAAAGACGGTACAAGGT-3  and 5 -ATC-
TTTTGGGTGCGATAATCCAGT-3 ,
(ix) p21 (accession number NM 007669), 5 -GAGAAC-
GGTGGAACTTTGACTTCG-3  and 5 -GCGCTT-
GGAGTGATAGAAATCTG-3 .
Levels of transcript ampliﬁcation were quantiﬁed by
using Image ProPlus software version 6.2, after normaliza-
tion with the gapdh transcript.
2.6. Myoblast Transfection. Transfections were carried
out by using Lipofectamine 2000 reagent (Invitrogen),
according to manufacturer’s instructions. L6E9 cells were
stably transfected with a MDAF2 vector containing the
myosin light chain promoter and 1/3 enhancer and simian
virus 40 processing sites, harboring a truncated dominant
negative form of murine Activin receptor type IIb that
lacks the kinase domain (dnActRIIb, aminoacids 1–174)
[15], together with a pBabe plasmid harboring a puromycin
gene resistance. L6E9 cells were also transfected with a
pBabe/follistatin vector, and transfectants were obtained
after antibiotic selection (2μg/mL).
2.7. Immunoblotting. Protein concentration was obtained by
bicinchoninic acid assay (Pierce). Total homogenates were
obtained by harvesting the myoblasts in cold RIPA lysis
buﬀer (1% Nonidet P40, 0.5% sodium deoxycholate, 0.1%
SDS in 50mM NaCl, 20mM Tris-HCl pH 7.6), containing a
mix of protease inhibitors (Roche). Samples were separatedJournal of Biomedicine and Biotechnology 3
by SDS-PAGE under reducing conditions and transferred
to nitrocellulose membranes. The following primary mouse
monoclonal antibodies (1:1000 diluted) were used: anti-
Myogenin (clone F5D, Santa Cruz Biotechnology), anti-
MyHC (Hybridoma Bank, University of Iowa), and anti-
Cav-3 (clone 26, BD Transduction Laboratories). A diluted
1:10000 antibody against tubulin (Sigma-Aldrich) was used
to normalize protein level content. Blots were then incubated
with secondary antibodies conjugated with horseradish
peroxidase (Chemicon) and Western Blots revealed with
enhanced chemiluminescence (Chemicon).
2.8. Statistics. All data are expressed as mean ± SEM. Statis-
tical signiﬁcance was determined using t-Student analysis. A
P value <.05 was considered signiﬁcant.
3. Results andDiscussion
3.1. L6E9 Myoblasts Provide a Spontaneous Myostatin Knock-
Out “In Vitro” Model. In this study we ﬁrst compared the
extent of diﬀerentiation between the mouse C2C12 and rat
L6E9 myoblasts, two cell lines that are commonly used for
myogenesis studies. After 2 and 4 days of low-serum treat-
ment, the myotubes appeared larger in L6E9 compared to
C2C12 cells, as morphologically visualized by phase contrast
images (Figure 1(a)). A graphical representation shows that,
after 4 days, the average size of L6E9 myotubes reached
about twofold of increase compared to C2C12 myotubes
(Figure 1(b)). Throughout the diﬀerentiation, the protein
levels of the muscle-speciﬁc markers myogenin, Caveolin
3 (Cav-3), and Myosin heavy chain (MyHC) increased
earlier in L6E9 compared to C2C12 cells, as detected by
immunoblotting (Figure 1(c)), suggesting that the fusion
process proceeds more rapidly in L6E9 cells. Subsequently,
we investigated whether the diﬀerent behavior of C2C12
and L6E9 myoblasts might reﬂect diﬀerent expression levels
of myostatin and follistatin, two secreted TGF-β family
members that exert profound and opposite eﬀects on muscle
mass, being a negative and positive regulator of muscle size,
respectively [15]. By semiquantitative RT-PCR analysis, we
detected that C2C12 cells express increasing levels of both
myostatin and follistatin during diﬀerentiation, whereas
L6E9 myoblasts lack myostatin despite the evident increase
of follistatin (Figure 1(d)). To rule out the possibility that
the primers designed for amplifying myostatin were not
speciﬁc for the rat isoform, we performed an RT-PCR by
using samples obtained from mouse and rat gastrocnemius
muscles. As shown in Figure 1(e), the primers speciﬁcally
produced the 377bp long fragment of myostatin in both
mouse and rat tissues, conﬁrming therefore that L6E9 cells
lack endogenous expression of myostatin. Additionally, we
veriﬁed that both the cell lines constitutively express the
transcripts for Activin receptors (ActRIIs), type IIa and
IIb (ActRIIa and b) (Figure 1(d)), which are the TGF-β
receptors that bind myostatin with low and high aﬃnity,
respectively [15]. To prove whether ActRIIs receptors are
functional in L6E9 cells, we next administered 100 and
500ng/mL recombinant myostatin (r-mstn) in the medium
of diﬀerentiated L6E9 cells. Within 48 hours of treatment,
r-mstn promoted a morphological impairment of myotube
size compared to untreated cells, as shown by phase contrast
images (Figure 2(a)). The graph in Figure 2(b) shows that
r-mstn signiﬁcantly decreased the size of L6E9 myotubes
and triggered the downregulation of MyHC expression
with a dose-dependent eﬀect compared to untreated cells,
as detected by immunoblotting (Figure 2(c)). It has been
established that myostatin promotes the activation of both
Smad and Foxo pathways by triggering its own transcription
[23]. Therefore, we next controlled whether exogenous r-
mstn administration might restore the endogenous levels of
myostatin in L6E9 cells. As suggested by RT-PCR analysis,
endogenous myostatin transcript was undetectable in L6E9
myotubes even after treatment with 500ng/mL r-mstn up
to 48 hours (Figure 2(d)), whereas the transcript level of
p21, a downstream target of myostatin pathway [24], was
increased; under these conditions, follistatin expression was
downregulated and the transcript levels for ActRIIa and IIb
were unaﬀected (Figure 2(d)).
Collectively, these data show that the robust diﬀeren-
tiation observed in L6E9 is characterized by deﬁciency of
myostatin. Although the behavior of L6E9 cells cannot be
exclusively ascribed to this hallmark sign, it is conceivable
that these myoblasts take advantage of lack of myostatin and
simultaneous presence of follistatin throughout the diﬀeren-
tiation process. Additionally, L6E9 cells possess functional
ActRIIs, given that exogenous administration of recombi-
nant myostatin promoted myotube impairment. Since mul-
tiple TGF-β ligands have been suggested to converge on these
receptors [19], probably mimicking the action of myostatin,
it is possible that the size of L6E9 myotubes might be under
the control of additional regulators; in line with this hypoth-
esis, L6E9 myoblasts express follistatin, which is known to
antagonize multiple negative regulators of muscle mass [22].
3.2. Delivery of a Dominant-Negative ActRIIb Form or the
Increase of Follistatin Levels Enhances the Size of L6E9
Myotubes Independently on Myostatin. It has been estab-
lished that diﬀerent TGF-β proteins act to regulate the
size of skeletal muscle mass in vivo. This evidence was
ﬁrst provided by the fact that follistatin transgenic mice
display a muscle mass that is greatly increased compared
to myostatin knock-out mice, suggesting that follistatin has
the unrivalled ability to bind and neutralize the activity
of additional myostatin-like regulators [19]. Therefore, we
wanted to verify whether the size of L6E9 myotubes might
be incremented irrespective of myostatin expression. To this
purpose, L6E9 cells were stably transfected with a dominant-
negative truncated ActRIIb form (dnActRIIb), which has
beendescribedtoinducedoublingofmusclemassinmicevia
abolition of myostatin signaling [15]. Additionally, in order
to increase follistatin, we exposed L6E9 cells to treatment
with the histone deacetylases inhibitor Trichostatin (TSA)
[18] or delivered into L6E9 myoblasts a vector encoding a
short human follistatin form. As shown by RT-PCR analysis
carried out over a time-course diﬀerentiation of three
days (Figure 3(a)), the amount of ActRIIb was remarkably
increased in dnActRIIb transfectants compared to control,4 Journal of Biomedicine and Biotechnology
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Figure 1: (a) Morphological visualization of C2C12 and L6E9 myoblasts undergoing diﬀerentiation. After Giemsa staining, phase contrast
pictures were taken under the same magniﬁcation. Bar=100μm. (b) The graph represents the quantiﬁcation of myotube average size in
diﬀerentiating C2C12 and L6E9 cells.
∗P <. 05. (c) Immunoblotting was performed to compare the time-course expression of myogenin,
Cav-3andMyHCbetweenC2C12andL6E9cells.Tubulinwasusedasloadingcontrol.(d)SemiquantitativeRT-PCRanalysiswasperformed
to detect the transcript levels of myostatin, follistatin, ActRIIa, and ActRIIb in C2C12 and L6E9 cells cultured in diﬀerentiating medium.
Gapdh ampliﬁcation was performed as loading control. (e) RT-PCR analysis was carried out to amplify a 377bp long fragment of myostatin
in both mouse and rat gastrocnemius muscles. The ampliﬁcation was performed by using the total RNA processed in presence or absence of
reverse transcriptase (RT+ or RT−, resp.). Total RNAs are shown as loading control.Journal of Biomedicine and Biotechnology 5
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Figure 2: (a) Morphological visualization of L6E9 myotubes, untreated (control, day 5) or treated at day 3 with 100 or 500ng/mL
recombinant myostatin (r-mstn) up to 48 hours, as depicted by phase contrast pictures after Giemsa staining. Bar = 100μm. (b) The graph
represents the quantiﬁcation of average size in L6E9 myotubes, treated with 100 or 500ng/mL r-mstn up to 48 hours as compared to control.
∗P <. 05 versus control. (c) Immunoblotting shows that MyHC levels are downregulated in L6E9 myotubes exposed to r-mstn (100 or
500ng/mL) up to 48 hours as compared to untreated cells. Tubulin was used as loading control. (d) Semiquantitative RT-PCR analysis was
performed to detect the expression levels of myostatin, p21, follistatin, ActRIIa, and ActRIIb in L6E9 myotubes (day 3) treated with r-mstn
(500ng/mL) up to 48 hours compared to untreated. Gapdh ampliﬁcation was performed as loading control.
because of the combined ampliﬁcation of both the full-
length endogenous and the truncated ectopic form. Under
these conditions, dnActRIIb cells also displayed increased
endogenous follistatin levels compared to control cells.
After TSA treatment or delivery of follistatin transgene, the
levels of follistatin were strongly increased over the entire
kinetic of diﬀerentiation compared to control cells, whereas
the levels of ActRIIb remained unchanged (Figure 3(a)).6 Journal of Biomedicine and Biotechnology
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Morphologically, each treatment was eﬀective to promote
a remarkable increase of L6E9 diﬀerentiation, characterized
by formation of myotubes that were signiﬁcantly larger
compared to control (Figure 3(b)). As shown by graphical
representation (Figure 3(c)), delivery of either dnActRIIb or
follistatin produced a signiﬁcant increase of the average size
compared to control; after TSA treatment, the diﬀerences in
myotube size became statistically signiﬁcant after day 2 of
treatment compared to control. Under these conditions, the
protein levels of myogenin, Cav-3, and MyHC were remark-
ably increased, although with diﬀerent timing, compared to
untreated cells (Figure 3(d)).
Collectively, these data conﬁrm that the regulation of size
in L6E9 myotubes occurs regardless of myostatin but still
under the control of additional TGF-β members, because
either blunting the ActRIIs signaling or increasing follis-
tatin expression enhanced the diﬀerentiation and further
improved the development of myotubes in vitro, as occurs
in vivo [15, 19].
3.3. L6E9 Myoblasts Express the TGF-β Family Members
Activins and GDF11. Myostatin signals into myoblasts
through a canonical TGF-β pathway, by eliciting the for-
mation of a ternary Smad complex that can drive to
gene transcription in collaboration with coactivators and
repressors [25]. Therefore, the regulators that potentially
display a myostatin-like activity presumably activate this
pathway, whereas myostatin antagonists, such as follistatin,
can antagonize it. The superfamily of TGF-β includes over
50 structurally related ligands that belong to three major
subfamilies, which are TGF-β, bone morphogenetic proteins
(BMPs), and Activins [26]. Recently, Activins A and B have
received a growing attention for their ability to regulate
the ﬁber size [20, 27]. Activins and myostatin share the
binding site on ActRIIs, suggesting that they can eventually
synergize to activate the Smad pathway [28]. Addition-
ally, another member of TGF-β family, termed GDF11
(Growth/Diﬀerentiation Factor 11), shares 90% aminoacid
identity with myostatin in carboxy-terminal region [20].
Therefore, the expression of Activins and GDF11 was
evaluated by means of semiquantitative RT-PCR analysis
in both L6E9 and C2C12 myoblasts. As shown by gel
analysis (Figure 4(a)) and by relative band quantiﬁcation
(Figure 4(b)), myostatin was found to increase exclusively
in C2C12 cells, whereas follistatin increased over the diﬀer-
entiation of both the cell lines. Under these conditions, the
expression of Activins A, B, and GDF11 was detectable in
both C2C12 and L6E9 myoblasts; in particular, during the
diﬀerentiation, GDF11 and Activin B levels were decreased
in both the cell lines, whereas Activin A was unaﬀected.
Taken together, these data suggest that L6E9 cells, despite
lack myostatin, express Activins and GDF11, which could be
potentially involved in the regulation of myotube size.
4. Conclusions
In this work, we provide evidence that L6E9 myoblasts
are spontaneously lacking myostatin. Additionally, we have
veriﬁed that the size of L6E9 myotubes can be incremented
through delivery of a dominant-negative ActRIIb form or
increase of follistatin, conﬁrming that multiple TGF-β reg-
ulators converge on ActRIIs receptors to determine the size
of myoﬁbers [19–21, 28, 29] and, importantly, that follistatin
can neutralize most of them [19, 20, 22, 29, 30]. In addition
to myostatin, GDF11, Activins (A and B) [29, 31], and
BMP-9 and 10 proteins have been identiﬁed to bind ActRIIs
[31]. However, whereas BMP-9 and 10 seem to convert
C2C12 myoblasts in the osteoblast lineage [20], GDF11 and
Activins exert an inhibitory eﬀect on myocyte diﬀerentiation
similar to myostatin, and their activity is neutralized by
follistatin[22,27].Recently,generationofmicewithablation
of both myostatin and GDF11 provided evidence that these
two highly related TGF-β members have redundant and
overlapping roles in regulating skeletal patterning but not
in regulating muscle size [32]. Therefore, in addition to
myostatin, Activins seem to play a major role in regulating
the myoﬁber size. In line with these observations, it would be
ofinteresttouseL6E9myoblastsfordissectingthecontribute
of myostatin-like molecules, such as Activins, GDF11, or
speciﬁc BMP proteins, or follistatin-like molecules, such as
decorin [33], which have the ability to neutralize multiple
negative regulators. Overall, we propose L6E9 myoblasts
as a suitable myostatin knock-out in vitro model to study
the mechanisms underlying the developmental regulation of
muscle ﬁbers.
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